Potential Use of Microbial Surfactant in Microemulsion Drug Delivery System: A Systematic Review
Received 24 September 2019
Accepted for publication 15 January 2020
Published 5 February 2020 Volume 2020:14 Pages 541—550
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 2
Editor who approved publication: Dr Anastasios Lymperopoulos
Mandana Ohadi,1 Arash Shahravan,2 Negar Dehghannoudeh,3 Touba Eslaminejad,1 Ibrahim M Banat,4 Gholamreza Dehghannoudeh1,5
1Pharmaceutics Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran; 2Endodontology Research Center, Kerman University of Medical Sciences, Kerman, Iran; 3Faculty of Arts and Science, University of Toronto, Toronto, Ontario, Canada; 4Faculty of Life & Health Sciences, University of Ulster, Coleraine BT52 1SA, N. Ireland, UK; 5Department of Pharmaceutics, Faculty of Pharmacy, Kerman University of Medical Sciences, Kerman, Iran
Correspondence: Gholamreza Dehghannoudeh Tel +98-34-31325015
Background: Microemulsions drug delivery systems (MDDS) have been known to increase the bioavailability of hydrophobic drugs. The main challenge of the MDDS is the development of an effective and safe system for drug carriage and delivery. Biosurfactants are preferred surface-active molecules because of their lower toxicity and safe characteristics when compared to synthetic surfactants. Glycolipid and lipopeptide are the most common biosurfactants that were tested for MDDS. The main goal of the present systematic review was to estimate the available evidence on the role of biosurfactant in the development of MDDS.
Search Strategy: Literature searches involved the main scientific databases and were focused on the period from 2005 until 2017. The Search filter composed of two items: “Biosurfactant” and/or “Microemulsion.”
Inclusion Criteria: Twenty-four studies evaluating the use of biosurfactant in MDDS were eligible for inclusion. Among these 14 were related to the use of glycolipid biosurfactants in the MDDS formulations, while four reported using lipopeptide biosurfactants and six other related review articles.
Results: According to the output study parameters, biosurfactants acted as active stabilizers, hydrophilic or hydrophobic linkers and safety carriers in MDDS, and among them glycolipid biosurfactants had the most application in MDDS formulations.
Conclusion: Synthetic surfactants could be replaced by biosurfactants as an effective bio-source for MDDS due to their excellent self-assembling and emulsifying activity properties.
Keywords: microemulsion, drug delivery systems, biosurfactant, systematic review glycolipid, lipopeptide
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]